Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -249.94% is 59% above its 5-year average of -610.53%, near the high end of its 5-year range (-1874900.00%–21.59%).
85.92% above its 12-month average of -1774.78%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 12.40%.
NET PROFIT MARGIN
-249.94%
NET PROFIT MARGIN AVG TTM
-1774.78%
NET PROFIT MARGIN AVG 3Y
-938.04%
NET PROFIT MARGIN AVG 5Y
-610.53%
NET PROFIT MARGIN AVG 10Y
-690.89%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+85.92%
CURRENT VS 3Y AVG
+73.35%
CURRENT VS 5Y AVG
+59.06%
CURRENT VS 10Y AVG
+63.82%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
AC Immune S.A.
Market Cap
$262.58M
Net Profit Margin
-249.94%
TTM Avg
-1774.78%
3Y Avg
-938.04%
5Y Avg
-610.53%
Market Cap
$260.03M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$262.48M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$256.35M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$263.68M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
Market Cap
$255.24M
Net Profit Margin
-8.78%
TTM Avg
-964.82%
3Y Avg
-2640.79%
5Y Avg
-1760.53%
Market Cap
$252.78M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$274.50M
Net Profit Margin
-1941.09%
TTM Avg
-1708.77%
3Y Avg
-990.85%
5Y Avg
-815.81%
Market Cap
$272.91M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AC Immune S.A. (ACIU) | $262.58M | -249.94% | -1774.78% | -938.04% | -610.53% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $260.03M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.35M | -3.14% | -28.33% | -34.54% | -25.62% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Century Therapeutics, Inc. (IPSC)vs › | $255.24M | -8.78% | -964.82% | -2640.79% | -1760.53% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $252.78M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Fate Therapeutics, Inc. (FATE)vs › | $274.50M | -1941.09% | -1708.77% | -990.85% | -815.81% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| Invivyd, Inc. (IVVD)vs › | $244.02M | -183.90% | -383.83% | -191.92% | -127.94% |
Operating Margin
-1927.3%
Net Profit Margin
-249.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 12.40% |
| 2026-03-31 | -1322.70% |
| 2025-12-31 | -4252.37% |
| 2025-09-30 | -1688.82% |
| 2025-06-30 | -1622.43% |
| 2025-03-31 | -1922.12% |
| 2024-12-31 | -1389.36% |
| 2024-09-30 | 21.59% |
| 2024-06-30 | -3312.95% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -32.05% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -1874900.00% |
| 2022-09-30 | -343.57% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | -2065.68% |
| 2020-09-30 | -1691.36% |
| 2020-06-30 | -1453.19% |
| 2020-03-31 | -62.61% |
| 2019-12-31 | -2261.16% |
| 2019-09-30 | 54.51% |
| 2019-06-30 | -1118.40% |
| 2019-03-31 | 84.72% |
| 2018-12-31 | -1046.12% |
| 2018-09-30 | -586.38% |
| 2018-06-30 | -549.46% |
| 2018-03-31 | -796.57% |
| 2017-12-31 | 25.36% |
| 2017-09-30 | -818.72% |
| 2017-06-30 | -1637.05% |
| 2017-03-31 | -471.34% |
| 2016-12-31 | -333.36% |
| 2016-09-30 | -682.82% |
| 2016-06-30 | 64.84% |
| 2016-03-31 | -1267.97% |
| 2015-12-31 | -1772.70% |
| 2015-09-30 | 82.46% |
| 2015-06-30 | 60.62% |
| 2015-03-31 | -1261.70% |
| 2014-12-31 | 76.14% |
| 2014-09-30 | -2366.49% |
| 2014-06-30 | -113.77% |
| 2014-03-31 | -113.77% |
